Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2016-03-17
Original market date: See footnote 1
2016-03-17
Product name:
BLINCYTO
Description:
LYOPHILIZED POWDER. FOR I.V. INFUSION.
DIN:
02450283
Product Monograph/Veterinary Labelling:
Date:
2024-04-26
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
AMGEN CANADA INC
300
6775 Financial Drive
Mississauga
Ontario
Canada
L5N 0A4
Class:
Human
Dosage form(s):
Powder For Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription , Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01FX07 BLINATUMOMAB
Active ingredient group (AIG) number:See footnote5
0157670001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| BLINATUMOMAB | 38.5 MCG / VIAL |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.
| Additional Risk Minimization Measures |
|---|
| Controlled Distribution Program |
| Healthcare Professional Education |
| Patient Wallet Card |